The last decade has been a mixed bag for leading Indian pharmaceutical companies. The dream run in the initial few years turned into a nightmare after 2015, as operating in the US market became challenging. Increasing competition, high price erosion, and quality-compliance issues made it difficult for most companies to grow their US business and get good returns. This affected the earnings of several companies that had significant exposure to
Business News›Prime›Pharma›Injectables and domestic foray: the two prongs of Aurobindo Pharma’s fix for a financial quirk
Strategy
Injectables and domestic foray: the two prongs of Aurobindo Pharma’s fix for a financial quirk
Synopsis
It is India’s second-largest pharma company by revenue but lags its peers in valuation and market cap. Its promoters are, therefore, taking corrective steps. Its injectables business is being restructured into a separate entity, and a foray into the domestic formulations business is in the offing. But will these be enough for Aurobindo Pharma to pull away from the pack?
Get Unlimited Access to The Economic Times
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal AdsComment & Engage with ET Prime community Exclusive invites to Virtual Events with Industry Leaders A trusted team of Journalists & Analysts who can best filter signal from noise
